Paging Dr. GPT? Tech Investors Bet AI Finally Poised to Transform Health Care – Yahoo Finance

(Bloomberg) — Top venture firms are betting that rapid advances in artificial intelligence and the public fascination with ChatGPT will help tech startups to transform health care after years of Silicon Valley struggling to move the needle in the industry.
Most Read from Bloomberg
Huawei Teardown Shows Chip Breakthrough in Blow to US Sanctions
Why China Is Avoiding Using ‘Bazooka’ to Spur Economy
Mercedes Bets on Range Boost in Swipe at Tesla’s EV Lead
Diamond Prices Are in Free Fall in One Key Corner of the Market
Andreessen Horowitz has been investing in a steady stream of startups that are looking to capitalize on the AI boom to improve medical care. That includes companies building AI tools to help with patient care and reduce the burden of clinical note-taking, as well as using AI to try to discover new drugs more quickly than traditional methods. Last week, the firm co-led a $200 million round in the AI-powered drug discovery company, Genesis Therapeutics. General Catalyst, Menlo Ventures, Lux Capital and others are also investing in AI health care startups.
These investments mirror the enthusiasm among larger tech companies like Microsoft Corp., Inc. and Alphabet Inc.’s Google, which are moving aggressively to expand their footprints in the lucrative health care industry. In July, Amazon unveiled HealthScribe, a generative AI tool that can help health care providers summarize doctors visits. Google is also said to be testing a medical chatbot in hospitals.
But health care, which is tightly regulated and still relies heavily on fax machines, has proven uniquely difficult for tech companies to crack. International Business Machines Corp. sold off some Watson Health assets last year, a setback for its goal to use AI to help health care providers analyze data and revolutionize cancer treatment. Amazon, meanwhile, abandoned a high-profile attempt to disrupt the industry with JPMorgan Chase & Co and Berkshire Hathaway Inc. Moreover, the large language models underpinning generative AI tools like ChatGPT are known to get details wrong, which could be especially problematic when dealing with complex and high-stakes situations like health care.
Vijay Pande, a general partner at Andreessen Horowitz, knows “the AI hype cycle has hit healthcare before,” as he put it in a blog post last month. But Pande, who has been beating the drum about AI’s potential impact on health care for nearly a decade at the firm, said it’s different now as the technology has improved significantly. He also notes that, like the evolution of the internet, real change takes time.
“It took 20 years for the internet to really transform everything,” Pande told Bloomberg. He likens the current state of AI in health care to where the internet was in 2005. The internet had started to seep into everyday life, but “we weren’t doing everything in our lives on the internet that we are today.”
While overall investment in AI startups has exploded this year, the picture for AI health care startups is more complicated. The category is currently pacing behind the $7.4 billion in funding raised last year, according to data from research firm PitchBook, and well below the $10.5 billion raised in 2021.
“AI has certainly been the buzzword on the tip of everyone's tongues,” especially in the health care industry, said Deena Shakir, general partner at Lux Capital. Still, she said, “there seems to be consensus that it's too early to know what the real impact will be.”
Here are some of the health care areas where tech investors are hoping for the most momentum.
Drug Discovery
Large pharmaceutical companies, along with a slew of newer entrants, are betting AI will speed up the process of discovering new drugs and therapies by combing through and analyzing vast data sets. These efforts predate the rise of ChatGPT and have had mixed success, but heightened attention on AI and advances in the technology could help boost momentum.
Rezo Therapeutics, a drug discovery startup, raised $78 million from investors including Andreessen Horowitz last fall and is focusing initially on cancer treatments. Chief Executive Officer Nevan Krogan, who is also the director of the Quantitative Biosciences Institute at the University of California, San Francisco, said Rezo aims to translate research from about 35 labs into therapies. “One of the things we’re trying to do is blur the lines between academia and biotech,” he said.
Krogan said he is preparing to raise a larger round of funding this year for his company, given the “huge appetite” from investors for Rezo and all things AI. “It’s been heating up over the last several months for good reason.”
Other startups are sitting out the AI funding boom, for now. Insitro raised about $700 million prior to the rise of ChatGPT and is using AI to develop therapeutics for fatty liver disease and tuberous sclerosis complex, a rare disease that causes neurological issues in children.
Daphne Koller, Insitro Inc.’s CEO, said the company isn’t planning to raise more funding in the near future, having ended last year with more than $500 million in the bank. She’s not worried about trying to capitalize on the AI hype cycle. “I try and think about substance,” said Koller, who has worked in the machine learning industry since the 1990s. “I don’t like to think of FOMO,” she added, referring to the fear of missing out.
Generative AI, which can produce written work and images in response to user prompts, has already been used by workers to help send emails, summarize long texts and streamline other routine administrative tasks. Now some tech companies are trying to apply this to health care.
Ambience Healthcare, for example, makes an AI-powered “scribe” to turn doctor-patient conversations into notes that the company claims saves clinicians about 16 hours per week that they’d otherwise spend writing information and referrals. Ambience has raised $30 million from investors, including Andreessen Horowitz and ChatGPT-creator OpenAI.
A growing list of other startups and larger tech companies offer similar clinical notes services, including Microsoft, Amazon and Doximity. There are limits, however. Some AI-powered services have reportedly been found to make errors in the process, requiring human contractors to intervene.
The US has a doctor shortage but don’t expect AI to replace physicians yet. There are concerns that relying too much on AI to triage cases could end up doing harm to patients by missing or misdiagnosing issues.
Hippocratic AI announced it raised $50 million from Andreessen Horowitz and General Catalyst in May to build large language models – the technology that underpins AI chatbots – specific to the healthcare industry. The company says it is focusing on tasks like explaining pre-operation instructions to patients, but it’s staying away from medical diagnoses — at least for now.
“We actually don’t think that generative AI is ready to do diagnoses — we think diagnoses need to come much later, when these models are safe,” CEO Munjal Shah previously told Bloomberg. “You have many other roles that are supporting roles and supporting actors in the health care system that really could benefit from generative AI.”
Most Read from Bloomberg Businessweek
Is Carlos Alcaraz the Next Billion-Dollar Tennis Player?
How a Tiny Mexican Border City Built a Budget Dental Empire
The Hostile Takeover of Blue Cities by Red States
Nigeria’s Train to Nowhere Shows How Not to Build Public Transit
Can You Name These Cities?
©2023 Bloomberg L.P.
(Bloomberg) — China’s top economic planner is creating a new department to help private businesses, the latest step by the government to revive confidence in the sector and bolster growth.Most Read from BloombergHuawei Teardown Shows Chip Breakthrough in Blow to US SanctionsWhy China Is Avoiding Using ‘Bazooka’ to Spur EconomyMercedes Bets on Range Boost in Swipe at Tesla’s EV LeadDiamond Prices Are in Free Fall in One Key Corner of the MarketThe private economy development bureau will be respo
(Bloomberg) — Alibaba Group Holding Ltd.’s cloud division is weighing a private round to raise funds from Chinese state-owned enterprises ahead of the business’s market debut in Hong Kong, people with knowledge of the matter said.Most Read from BloombergHuawei Teardown Shows Chip Breakthrough in Blow to US SanctionsWhy China Is Avoiding Using ‘Bazooka’ to Spur EconomyMercedes Bets on Range Boost in Swipe at Tesla’s EV LeadDiamond Prices Are in Free Fall in One Key Corner of the MarketThe tech g
Two big names have already agreed to pay more than $15 billion to resolve lawsuits and the numbers are expected to get a lot higher before it's all over.
Long-term care in residential facilities like nursing homes is a financial challenge for many. When dealing with a loved one who is disabled, elderly or ill, families often try every other kind of long-term care facility first. Because nursing homes … Continue reading → The post Nursing Home Costs: How You Can Cover Them appeared first on SmartAsset Blog.
People in Britain who can afford to pay out of their own pocket may get easier access to Novo Nordisk's weight-loss drug Wegovy than those seeking treatment in the country's state-run health service, some doctors and medical experts warned on Monday. That risks worsening health inequality in the country with the highest obesity levels in Europe when Britain's National Health Service (NHS) is under increasing financial strain and struggling with record waiting times.
Abbott's (ABT) latest late-breaking data reflects OCT's potential to improve clinical practice related to stent placement.
Centessa (CNTA) shares rise significantly in the past three months due to the encouraging progress in the development of its lead pipeline candidate, SerpinPC, which is currently in mid-late-stage studies.
A lot of scary things happened during the COVID-19 pandemic, but one that looms large for a lot of people is the huge share of deaths that took place in nursing homes. A new brief from the Center for Retirement … Continue reading → The post If COVID Scared You Off Nursing Homes, Don't Delay Your Financial Plan for Aging in Place appeared first on SmartAsset Blog.
Imugene Ltd (ASX:IMU, OTC:IUGNF) CEO Leslie Chong speaks with Proactive soon after the company announced it has cleared the first cohort of patients of the intratumoral (IT) arm of its VAXINIA meta…
Bladder health isn't the sexiest subject in the world so it probably won't surprise you there are so few startups focused on the area. Only one actually, according to Jude founder Peony Li — who's just closed a $4.24 million seed round for her London-based bladder health startup to expand into the US. The startup says there are 2.3 billion people experiencing some form of bladder problem, whether it's an overactive bladder, leaking or incontinence, or recurring urinary infections.
Charlie Munger, Warren Buffett's right-hand man, spent $1,000 on oil royalties in 1962. He now receives 70 times that amount from them each year.
Homeowners are facing a “cost of owning crisis” as rapidly falling house prices push tens of thousands into negative equity.
With the stock market closed for Labor Day, it could be a good time to take a step back and look at what’s happening with U.S. government bonds. One is short-term interest rates, set by the Federal Reserve. The other is the outlook for inflation, since consumer-price gains erode the returns of interest-bearing securities.
While Rivian (RIVN) unveils that its latest dual-motor R1T boasts an impressive 410-mile range, Fisker (FSR) is actively advancing its global presence by expanding into new European markets.
After selling his instant noodle business to Nestle for $150 million, Pham Nhat Vuong invested in Vietnam's luxury real estate market and hit it big.
Jeremy Siegel says a brighter earnings outlook, and the prospect of no more interest-rate hikes until at least December, are good news for stocks.
What might seem to be farfetched tax mitigation tactics are perfectly legal, lawyers and bankers to the wealthy tell Insider.
Raleigh, North Carolina, September 4, 2023 (500NewsWire) — Reverse Health proudly presents the first lifestyle-based program focused on menopause. Designed to provide comprehensive support for wom…
US equity investors are in for disappointment as economic growth is set to be weaker than expected this year, according to Morgan Stanley’s staunch bear, Michael Wilson.
Auto makers and chip stocks were among the big movers at the start of a shortened week following the Labor Day holiday.